Keybanc analyst Brett Andress downgrades YETI Holdings (NYSE:YETI) from Overweight to Sector Weight.
Sonnet BioTherapeutics Q1 EPS $(0.10) Up From $(0.34) YoY
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.10) per share. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.